Work

Effect of manidipine-simvastatin combination on fibrinolysis, adhesion molecules and C-reactive protein in hypertensive hypercholesterolemic patients

Year: 2005

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Abstract: Aim of this study was to evaluate the effect of manidipine-simvastatin combination on plasma tissue plasminogen activator (t-PA) and inhibitor (PAI-1) activity, on plasma intercellurar adhesion molecule type-1 (ICAM-1) and on serum C-reactive protein (CRP) in hypertensive, hypercholesterolemic patients. After 4 week placebo run-in period, 36 hypertensive [diastolic blood pressure (DBP) > 90 and < 105 mmHg], hypercholesterolemic [total cholesterol (TC) > 200 mg/dl] patients were randomized to manidipine 20 mg or simvastatin 40 mg or manidipine-simvastatin combination, according to a 3 x 3 cross over design; each treatment had 12 week duration. Thirty patients completed the study. The last day of the placebo run-in period and of each treatment period blood pressure was measured and a venous blood sample was taken (at the same hour in the morning) to evaluate plasma t-PA and PAI-1 activity, TC, plasma ICAM-1 and CRP. The main results are shown in the table. Main Results *p < 0.05; **p < 0.01; ***p < 0.001 vs placebo These results suggest that in hypertensive, hyperchoelsterolemic patients manidipine-simvastatin combination improves the fibrinolytic balance, reduces the plasma ICAM-1 and decreases BP more than single monotherapy. The concomitant cholesterol and CRP reduction suggests that manidipine-simvastatin combination could be the treatment of choice in hypertensive hypercholesterolemic patients.

Source: American Journal of Hypertension

DOI: 10.1016/j.amjhyper.2005.03.471